We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$740M
AUM Growth
-$43.3M
Cap. Flow
-$86.3M
Cap. Flow %
-11.66%
Top 10 Hldgs %
29.49%
Holding
104
New
10
Increased
27
Reduced
49
Closed
9

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.8M
2
GILD icon
Gilead Sciences
GILD
+$9.89M
3
COR icon
Cencora
COR
+$7.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.72M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$6.41M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$20.2M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$14.8M
3
ABMD
Abiomed Inc
ABMD
+$10M
4
AET
Aetna Inc
AET
+$9.86M
5
CVS icon
CVS Health
CVS
+$9.76M

Sector Composition

Rank Sector Weight
1 Healthcare 90.07%
2 Financials 0.19%
3 Technology 0.17%
4 Energy 0.14%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
51
Agios Pharmaceuticals
AGIO
$1.93B
$5.72M 0.77%
100,000
+85,000
+567% +$5.35M
HCA icon
52
HCA Healthcare
HCA
$89.5B
$5.17M 0.7%
58,886
+8,886
+18% +$714K
ELGX
53
DELISTED
Endologix Inc
ELGX
$5.12M 0.69%
95,600
-53,660
-36% -$2.83M
JUNO
54
DELISTED
Juno Therapeutics, Inc.
JUNO
$5M 0.68%
109,430
+9,430
+9% +$470K
PBYI icon
55
Puma Biotechnology
PBYI
$454M
$4.94M 0.67%
+50,000
New +$5.6M
BIIB icon
56
Biogen
BIIB
$30.7B
$4.87M 0.66%
15,300
-6,700
-30% -$2.15M
WBA
57
DELISTED
Walgreens Boots Alliance
WBA
$4.77M 0.64%
65,700
-4,300
-6% -$303K
DVAX
58
DELISTED
Dynavax Technologies
DVAX
$4.54M 0.61%
242,812
-131,725
-35% -$2.64M
CNC icon
59
Centene
CNC
$32.5B
$4.54M 0.61%
90,000
-130,000
-59% -$6.3M
RARE icon
60
Ultragenyx Pharmaceutical
RARE
$2.55B
$4.41M 0.6%
95,000
-5,000
-5% -$245K
LIVN icon
61
LivaNova
LIVN
$4.2B
$4.24M 0.57%
53,000
-42,000
-44% -$3.33M
SGMO
62
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.2M 0.57%
+255,793
New +$3.81M
DXCM icon
63
DexCom
DXCM
$32B
$4.05M 0.55%
282,500
-197,500
-41% -$2.57M
ONCE
64
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$3.61M 0.49%
+70,200
New +$5.04M
ALKS icon
65
Alkermes
ALKS
$8.25B
$3.22M 0.43%
58,800
-86,200
-59% -$4.4M
CHRS icon
66
Coherus Oncology
CHRS
$196M
$3.08M 0.42%
350,000
+170,000
+94% +$1.82M
OMCL icon
67
Omnicell
OMCL
$1.68B
$2.83M 0.38%
58,445
-21,555
-27% -$1.09M
EPZM
68
DELISTED
Epizyme, Inc
EPZM
$2.73M 0.37%
217,591
-18,702
-8% -$272K
DERM
69
DELISTED
Dermira, Inc.
DERM
$2.64M 0.36%
95,000
-5,000
-5% -$133K
VRAY
70
DELISTED
ViewRay, Inc.
VRAY
$2.62M 0.35%
+282,385
New +$2.26M
ICPT
71
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.25M 0.3%
38,500
-1,500
-4% -$94.6K
ZGNX
72
DELISTED
Zogenix, Inc.
ZGNX
$2.08M 0.28%
+51,808
New +$1.99M
ACHN
73
DELISTED
Achillion Pharmaceuticals
ACHN
$1.92M 0.26%
667,800
-182,200
-21% -$662K
VIRX
74
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.66M 0.22%
+12,860
New +$1.21M
CMRX
75
DELISTED
Chimerix, Inc.
CMRX
$1.58M 0.21%
342,000
-58,000
-15% -$276K
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Rhenman & Partners Asset Management held 104 positions worth $740M, down 5.5% from $783M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $86.3M in Q4 2017, closing 9 positions and reducing 49 holdings. Its most notable exit was Aetna Inc, an estimated $9.86M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier, followed by Financials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Acadia Pharmaceuticals worth $10.2M.

  • Rhenman & Partners Asset Management's largest Q4 2017 buy was Acadia Pharmaceuticals: 338,882 shares worth $10.2M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q4 2017, an estimated $9.89M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $20.2M.
  • Rhenman & Partners Asset Management fully exited Aetna Inc in Q4 2017, selling an estimated $9.86M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $740M portfolio in Q4 2017.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 9 in Q4 2017.
  • Rhenman & Partners Asset Management's portfolio value fell 5.5% quarter-over-quarter to $740M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2017, filed 19 Jan 2018.